Market Access BIO-Europe Spring 2026: In conversation with Marjorie Sidhou... Marjorie Sidhoum, vice president of business development & corporate communication at Kainova Therapeutics, discusses their immuno-oncology pipeline.
R&D Closed & Collaborative – January to February 2026 January and February this year weren't a story of a few dominant megadeals, but rather a dense constellation of cross‑disciplinary alliances.
R&D A playbook for effective sponsor/CRO partnership Find out more about optimising sponsor/CRO collaboration in an interview on a case study in FI cell therapy.
News Now Iktos teams up with Pierre Fabre in oncology As Servier announces its partnership with Paris, France-based Iktos, now Pierre Fabre Laboratories has revealed an integrated collaboration with Iktos
Sales & Marketing Why pharmacy-based engagement is pharma’s untapped adherence... Pharma companies can work alongside pharmacists to deliver personalised outreach that informs patient treatment decisions and drives adherence.
R&D Closed & Collaborative H2 2025: Mergers, acquisitions, partn... The second half of 2025 showed pharma and healthcare leaning into partnerships that de‑risk innovation and compress time to market.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.